PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278977ArticlesСтатьиCARBAPENEMS (IMIPENEM, MEROPENEM, DORIPENEM) IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA: CURRENT STATE OF THE PROBLEMКАРБАПЕНЕМЫ (ИМИПЕНЕМ, МЕРОПЕНЕМ, ДОРИПЕНЕМ) В ЛЕЧЕНИИ НОЗОКОМИАЛЬНОЙ ПНЕВМОНИИ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫBelousovaYuriy BorisovichБелоусоваЮрий Борисович

РГМУ

ZyryanovSergey KensarinovichЗыряновСергей Кенсаринович

РГМУ

ShteynbergLyudmila L'vovnaШтейнбергЛюдмила Львовна

РГМУ

BelousovYu BZyryanovS KShteynbergL LРГМУ150820111815NO15 (2011)№15 (2011)162324022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278977

Nosocomial pneumonia (NP) is one of the most common hospital-acquired infections and leading cause of mortality among such infections. Adequate empirical antibiotic therapy plays defininge role in the successful outcome of NP. Carbapenems (imipenem/cilastatin, meropenem, doripenem) are recommended as first-line therapy for advanced NP and/or risk factors for multi-resistant microorganisms. This review is aimed to summarize data for the use of various carbapenems in the treatment of NP, their comparative clinical and pharmacoeconomic efficiency.

Нозокомиальная пневмония (НП) является одной из самых частых внутрибольничных инфекций и занимает среди них первое место по смертности. Определяющую роль в благоприятном исходе НП играет адекватная эмпирическая антибактериальная терапия. Карбапенемы (имипенем/циластатин, меропенем, дорипенем) рекомендованы в качестве терапии первой линии при поздней НП и/или наличии факторов риска полирезистентной микрофлоры. Цель настоящего обзора - обобщить данные о применении различных карбапенемов в лечении НП, их сравнительной клинической и фармакоэкономической эффективности.

nosocomial pneumoniacarbapenemsimipenemmeropenemdoripenemнозокомиальная пневмониякарбапенемыимипенеммеропенемдорипенемЧучалин А.Г., Гельфанд Б.Р. Нозокомиальная пневмония у взрослых. Национальные рекомендации. 2009.American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005;171:388-416.Craven DE, Epidemiology of ventilator-associated pneumonia. Chest 2000;117(4).Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of Gram negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 2005;56(5): 893-98.Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemother 2005;51:227-33.Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin. Pharmacother 2008;9(4):561-75.Masterton RG, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008.Marin H, Kollef MD. Appropriate Empiric Antimicrobial Therapy of Nosocomial Pneumonia: The Role of the Carbapenems. Respir Care 2004;49(12):1530-41.Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infection: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122:2183-96.Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17(8):552-57.Arnold A, Brouse SD, William D. Pitcher and Ronald G. Hall II. Empiric Therapy for Gram-Negative Pathogens in Nosocomial and Health Care-Associated Pneumonia: Starting With the End in Mind. J Intensive Care Med 2010;25:259.Яковлев С.В. Нозокомиальные инфекции, вызванные полирезистентными грамотрицательными микроорганизмами: как с ними бороться? // Consilium Medicum 2008. Т. 10. № 1.Sumita Y, Fukasawa M, Okuda T. Affi nities of SM-7338 for penicillin binding protein and its release from these proteins in Staphylococcus aureus. Antimicrob Agents Chemother 1990;34(3):484-6.Sumita Y, Fuksawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin binding protein and morphological changes. J Antibiot (Tokyo) 1990;43(3):314-20.Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against Gram negative bacteria with a permeability defect against staphylococci. J Antimicrob Chemother 1989;24:125-132.Rhomberg PR, Ronald NJ. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Disease 2008;65(4):414-26.Nordmann P, Picazo JJ, Mutters R, et al. Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 2011.Castanheira M, Jones RN, Livermore DM. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis. 2009;63(4):426-33.Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofl oxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38(3):547-57.Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients; a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47(11):3442-7.Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and pipercillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42(11):2966-72.Torres A, Bauer TT, Leon-Gill C, et al. Treatment of severe nosocomial pneumonia: a prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000;55:1033-39.Schmitt DV, Leitner E, Welte T, et al. Pipercillin/Tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia - a double blind prospective multicentre study. Infection 2006;34:127-34.Joshi M, Metzler M, Mccarthy M, et al. Comparision of pipercillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006;100:1154-565.West M, Boulanger B, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;23(2):485-505.Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996;38:523-37.Garau J, Blanquer J, Cobo L, et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997;16:789-96.Alvarez-Lerma F, Santos FM, De Castro J, et al. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001;13(1):70-81.Santos SS, Machado FR, Kiffer CR, et al. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis2001;5(3):124-29.Berman SJ, Fogarty CM, Fabian T, et al. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004;16(4):362-71.Mouton YJ, Beuscart C. Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995;36:145-56.Jaspers C, Kieft H, Speelberg B, et al. Meropenem versus cefuroxime plus gentamicin for treatment for serious infections in elderly patients. Antimicrob Agents Chemother 1998;42:1233-38.Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68(6):803-38.Seiger B, Berman SJ, Geckler R, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997;25(10):1663-70.Jones RN, Huynh HK, Biedenbach, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54:144-54.Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various â ?-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52:71.Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48(8):3136-40.Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect Dis 2005;11:974-84.Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot 2006;59(4):220-8.Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48(8):3086-92.Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006;55(3):241-3.Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24(7):2113-26.Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36(4):1089-96.Alvarez-Lerma F, Grau S, Ferrandez O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Design Develop Ther 2009:3 173-190.Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30(5):868-83.Solomkin J, Umeh O, Jiang J. Doripenem versus Imipenem for the treatment of complicated intraabdominal infections. In programm and abstracts of the 47thICAAC; American society for microbiology.Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008;30(4):717-33.Kongnakorn T, Mwamburi M, Merchant S, et al. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin 2010;26(1):17-24.McGarry LJ, Merchant S, Nathwani D, et al. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia. J Med Econ 2010;13(1):142.